SCHEMBL6736737

SCHEMBL6736737

Cc1ccc(-c2[nH]c(C(F)(F)F)nc2-c2cc(F)c(S(C)(=O)=O)cc2F)cc1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 5/20 0.39
NR1H3 Q13133 5/20 0.39
NOTUM Q6P988 1/20 0.35
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
KIF11 P52732 1/20 0.34
PDE3B Q13370 3/20 0.34
PDE3A Q14432 3/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34
SCN9A Q15858 1/20 0.34
PTGS2 P35354 2/20 0.33
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
MAPK14 Q16539 1/20 0.33
ALOX5 P09917 1/20 0.33
S1PR1 P21453 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6736484 0.92 NR1H2 (0.39) NR1H2NR1H3ESR1ESR2KIF11
SCHEMBL6737168 0.92 PTGS2 (0.42) NR1H2NR1H3ESR1ESR2PTGS2
SCHEMBL6733585 0.90 PTGS2 (0.42) NR1H2NR1H3ESR1ESR2PTGS2
SCHEMBL6728472 0.89 PTGS2 (0.45) NR1H2NR1H3ESR1ESR2SCN9A
SCHEMBL6737092 0.89 NR1H2 (0.35) NR1H2NR1H3ESR1ESR2PIK3CD
SCHEMBL6723034 0.88 ESR1 (0.38) NR1H2NR1H3NOTUMESR1ESR2
SCHEMBL6736814 0.87 PTGS2 (0.40) NR1H2NR1H3ESR1ESR2PTGS2
SCHEMBL6735451 0.87 PTGS2 (0.38) NR1H2NR1H3ESR1ESR2KIF11
SCHEMBL6739124 0.87 NR1H2 (0.38) NR1H2NR1H3NOTUMKIF11PDE3B
SCHEMBL6728639 0.87 PTGS2 (0.45) NR1H2NR1H3ESR1ESR2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US claimed
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 NR1H2 173/4885NR1H3 299/4885NOTUM 3983/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 NR1H2 173/4885NR1H3 299/4885NOTUM 3983/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 NR1H2 173/4885NR1H3 299/4885NOTUM 3983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.